Background: L19-IL2, a tumour-targeting immunocytokine composed of the recombinant human antibody fragment L19 (specific to the alternatively-spliced EDB domain of fibronectin, a well characterised marker of tumour neo-vasculature) and of human IL2, has demonstrated strong therapeutic activity in animal cancer models. This phase I/II trial was ...

在这项研究中，研究人员在具有免疫功能的 神经胶质瘤 原位小鼠模型中测试了细胞因子IL-2、 IL-12 和TNF与抗体L19结合后（L19-IL2，L19-mTNF和L19-mIL12）的治疗效果（先前的研究表明，当 静脉注射 放射标记的基于L19的 抗体偶联物 时，L19会选择性地定位到患者原发性和继发性的 脑肿瘤 中）。 结果表明，相比于单独使用其中两种蛋白. 10月7日，在Science Translational Medicine上发表的一篇论文中，瑞士苏黎世大学医院和意大利生物技术公司Philogen等研究机 …

2018年1月16日 · Recently, we have shown that the administration of the tumour-targeted antibody-based immunocytokine L19-IL2 after radiotherapy (RT) resulted in synergistic anti-tumour effect. Here we show that RT and L19-IL2 can activate a curative abscopal effect, with a long-lasting immunological memory.

Here we describe the results of a controlled, randomized phase II clinical trial, aimed at assessing the therapeutic potential of L19IL2, a fully human fusion protein consisting of the L19 antibody specific to the alternatively spliced extra-domain B of fibronectin, fused to human interleukin-2 in advanced metastatic melanoma.

The cytokine interleukin 2 (IL2) stimulates the proliferation and differentiation of cytotoxic, helper and regulatory T cells, and natural killer (NK) cells, resulting in a balanced pro- and anti-inflammatory immune response. 20 IL2 treatment has shown durable and curative regressions in patients with metastatic melanoma, renal cancer and ...

2010年11月1日 · L19-IL2, a tumour-targeting immunocytokine composed of the recombinant human antibody fragment L19 (specific to the alternatively-spliced EDB domain of fibronectin, a well characterised marker of tumour neo-vasculature) and of human IL2, has demonstrated strong therapeutic activity in animal cancer models.

We recently reported that the intralesional injection of L19-IL2, an immunocytokine combining IL2 and the human monoclonal antibody fragment L19, resulted in efficient regional control of disease progression, increased time to distant metastasis and evidence of effect on circulating immune cell populations.

2018年1月16日 · Recently, we have shown that the administration of the tumour-targeted antibody-based immunocytokine L19-IL2 after radiotherapy (RT) resulted in synergistic anti-tumour effect. Here we show that RT and L19-IL2 can activate a curative abscopal effect, with a long-lasting immunological memory.

2013年3月1日 · The immunocytokine L19–IL2, in which IL2 is fused to the human L19 antibody capable of selective accumulation on tumor neovasculature, has recently shown encouraging clinical activity in patients with metastatic melanoma.

L19-IL2 is an immunocytokine composed of an scFv specific for the angiogenesis-associated B-fibronectin (B-FN) isoform and IL2 (interleukin 2) selectively accumulated on tumor neovasculature, and showed a good anti-tumor activity in preclinical models and PhaseI/II clinical trials, both in solid and hematological tumors [37,38,39,40]. In this ...